Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers
Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1422-0067/17/3/358 |
| _version_ | 1811221377390215168 |
|---|---|
| author | Yuanyuan Yu Chao Liang Quanxia Lv Defang Li Xuegong Xu Baoqin Liu Aiping Lu Ge Zhang |
| author_facet | Yuanyuan Yu Chao Liang Quanxia Lv Defang Li Xuegong Xu Baoqin Liu Aiping Lu Ge Zhang |
| author_sort | Yuanyuan Yu |
| collection | DOAJ |
| description | Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies whilst they have minimal immunogenicity, high production, low cost and high stability, thus are promising inhibitors to rival antibodies for disease therapy. In this review, we will compare the detailed advantages and disadvantages of antibodies and aptamers in therapeutic applications and summarize recent progress in aptamer selection and modification approaches. We will present therapeutic oligonucleotide aptamers in preclinical studies for skeletal diseases and further discuss oligonucleotide aptamers in different stages of clinical evaluation for various disease therapies including macular degeneration, cancer, inflammation and coagulation to highlight the bright commercial future and potential challenges of therapeutic oligonucleotide aptamers. |
| first_indexed | 2024-04-12T07:58:12Z |
| format | Article |
| id | doaj.art-e69476418f6a4f8aa2dba7b287d99111 |
| institution | Directory Open Access Journal |
| issn | 1422-0067 |
| language | English |
| last_indexed | 2024-04-12T07:58:12Z |
| publishDate | 2016-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-e69476418f6a4f8aa2dba7b287d991112022-12-22T03:41:25ZengMDPI AGInternational Journal of Molecular Sciences1422-00672016-03-0117335810.3390/ijms17030358ijms17030358Molecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersYuanyuan Yu0Chao Liang1Quanxia Lv2Defang Li3Xuegong Xu4Baoqin Liu5Aiping Lu6Ge Zhang7Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaInstitute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaInstitute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaInstitute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaZhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou 450007, ChinaZhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou 450007, ChinaInstitute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaInstitute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, ChinaMonoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies whilst they have minimal immunogenicity, high production, low cost and high stability, thus are promising inhibitors to rival antibodies for disease therapy. In this review, we will compare the detailed advantages and disadvantages of antibodies and aptamers in therapeutic applications and summarize recent progress in aptamer selection and modification approaches. We will present therapeutic oligonucleotide aptamers in preclinical studies for skeletal diseases and further discuss oligonucleotide aptamers in different stages of clinical evaluation for various disease therapies including macular degeneration, cancer, inflammation and coagulation to highlight the bright commercial future and potential challenges of therapeutic oligonucleotide aptamers.http://www.mdpi.com/1422-0067/17/3/358oligonucleotide aptamersmonoclonal antibodiesdiseases therapypreclinical studyclinical evaluation |
| spellingShingle | Yuanyuan Yu Chao Liang Quanxia Lv Defang Li Xuegong Xu Baoqin Liu Aiping Lu Ge Zhang Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers International Journal of Molecular Sciences oligonucleotide aptamers monoclonal antibodies diseases therapy preclinical study clinical evaluation |
| title | Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers |
| title_full | Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers |
| title_fullStr | Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers |
| title_full_unstemmed | Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers |
| title_short | Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers |
| title_sort | molecular selection modification and development of therapeutic oligonucleotide aptamers |
| topic | oligonucleotide aptamers monoclonal antibodies diseases therapy preclinical study clinical evaluation |
| url | http://www.mdpi.com/1422-0067/17/3/358 |
| work_keys_str_mv | AT yuanyuanyu molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT chaoliang molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT quanxialv molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT defangli molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT xuegongxu molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT baoqinliu molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT aipinglu molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers AT gezhang molecularselectionmodificationanddevelopmentoftherapeuticoligonucleotideaptamers |